As China Prices Drop, Junshi Looks To Coherus To Take PD-1 Global
Execs See China Deal Structure, Valuation Evolving
After Novartis, US firm Coherus leaps into the China immuno-oncology fray by licensing rights to innovative drugs from Shanghai's Junshi.
You may also be interested in...
PD-1 Inhibitor Market Poised For A New Round Of Expansion: After GSK’s Jemperli Approval, US FDA Still Has Three Novel Candidates Under Review
Agenus’ recent submission of balstilimab joins novel checkpoint inhibitors from Incyte expecting FDA action this year; Junshi and Coherus’ ongoing rolling BLA for toripalimab is the first from the multiple PD-1/L1 inhibitor candidates developed in China that are vying to enter the US market.
From relatively little-known to high-flying, hotly pursued targets by global pharma players, Chinese domestically developed immuno-oncology drugs are ascending in both value and attractiveness, both inside China and far beyond.
Plus deals involving Helixmith/Wacker, Sosei Heptares/Metrion, Ono/Ribon, Asahi Kasei/Lilly, Citrine/Diurnal, Mitsubishi Tanabe/Aquestive, Immunotech/T-Cure, TRIGR/Elpiscience, Daiichi Sankyo/ViGeneron